文献速递眼底病与葡萄膜炎

玻璃体腔注射5-氟尿嘧啶与肝素预防增生性玻璃体视网膜病变:一项随机临床试验结果

Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
PubMed 文献 · Ophthalmology · 2022-06-07

这项随机双盲多中心试验纳入325例原发性孔源性视网膜脱离且PVR高风险患者,玻璃体切割术中分别注射5-FU联合达肝素或安慰剂。改良意向治疗分析显示PVR发生率两组无显著差异(28% vs 23%,OR 1.25,95%CI 0.76-2.08,P=0.77),符合方案分析亦无差异(12% vs 12%),次要终点均无显著差异,未发现相关安全风险。

要点

  • 在高风险原发性孔源性视网膜脱离眼中,辅助玻璃体腔注射5-FU与低分子量肝素未降低PVR发生率。
  • 改良意向治疗分析PVR发生率:试验组28% vs 安慰剂组23%(OR 1.25,95%CI 0.76-2.08,P=0.77)。
  • 符合方案分析PVR发生率:试验组12% vs 安慰剂组12%(OR 1.05,95%CI 0.47-2.34,P=0.47)。

核心结论

  • 在原发性孔源性视网膜脱离眼中,辅助玻璃体腔注射5-FU与低分子量肝素组的PVR发生率与安慰剂组无差异。

研究设计与样本

  • 随机、双盲、对照、多中心、干预性试验,包含1次中期分析。
  • 共325例患者来自13个德国试验中心,随机分为试验组(n=163)和安慰剂组(n=162)。
  • 纳入标准为原发性孔源性视网膜脱离且经激光闪辉光度计测量前房闪辉评估为PVR高风险的患者。
  • 患者按1:1随机接受试验药物(200 mg/ml 5-FU与5 IU/ml达肝素)或安慰剂(平衡盐溶液)玻璃体腔注射,于常规平坦部玻璃体切割术中给药。

主要发现

  • 改良意向治疗分析中PVR发生率:试验组28% vs 安慰剂组23%(OR 1.25,95%CI 0.76-2.08,P=0.77),将不可评估病例计为失败。
  • 符合方案分析中PVR发生率:试验组12% vs 安慰剂组12%(OR 1.05,95%CI 0.47-2.34,P=0.47)。
  • 次要终点包括最佳矫正视力与再脱离率,两组间均未显示任何显著差异。
  • 研究期间未发现相关安全风险。

关键数值与推荐

  • 主要终点为术后12周内发生PVR CP级(赤道后钟点方位全层视网膜皱褶或视网膜下条索)1级或以上,由终点委员会评估眼底照片进行分级。
  • 使用O'Brien-Fleming界限进行含1次中期分析的成组序贯设计。
  • PVR CP级发生率比较采用按手术医生分层的Mantel-Haenszel检验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Proliferative vitreoretinopathy (PVR) is the major cause for surgical failure after primary rhegmatogenous retinal detachment (RRD). So far, no therapy has been proven to prevent PVR. Promising results for 5-fluorouracil (5-FU) and low-molecular weight heparin (LMWH) in high-risk eyes have been reported previously. The objective of this trial was to examine the effect of adjuvant intravitreal therapy with 5-FU and LMWH compared with placebo on incidence of PVR in high-risk patients with primary RRD. DESIGN: Randomized, double-blind, controlled, multicenter, interventional trial with 1 interim analysis. PARTICIPANTS: Patients with RRD who were considered to be at high risk for PVR were included. Risk of PVR was assessed by noninvasive aqueous flare measurement using laser flare photometry. METHODS: Patients were randomized 1:1 to verum (200 mg/ml 5-FU and 5 IU/ml dalteparin) and placebo (balanced salt solution) intravitreally applied during routine pars plana vitrectomy. MAIN OUTCOME MEASURES: Primary end point was the development of PVR grade CP (full-thickness retinal folds or subretinal strands in clock hours located posterior to equator) 1 or higher within 12 weeks after surgery. For grading, an end point committee assessed fundus photographs. Secondary end points included best-corrected visual acuity and redetachment rate. A group sequential design with 1 interim analysis was applied using the O'Brien and Fleming boundaries. Proliferative vitreoretinopathy grade CP incidence was compared using a Mantel-Haenszel test stratified by surgeon. RESULTS: A total of 325 patients in 13 German trial sites had been randomized (verum, n = 163; placebo, n = 162). In study eyes, mean laser flare was 31 ± 26 pc/ms. No significant difference was found in PVR rate. Primary analysis in the modified intention-to-treat population results were: verum 28% vs. placebo 23% (including not assessable cases as failures); odds ratio [OR], 1.25; 95% confidence interval [CI], 0.76-2.08; P = 0.77. Those in the per-protocol population were: 12% vs. 12%; OR, 1.05; 95% CI, 0.47-2.34; P = 0.47. None of the secondary end points showed any significant difference between treatment groups. During the study period, no relevant safety risks were identified. CONCLUSIONS: Rate of PVR did not differ between adjuvant therapy with 5-FU and LMWH and placebo treatment in eyes with RRD.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Schaub F, Schiller P, Hoerster R, et al. Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial. Ophthalmology. 2022. PMID: 35680097. doi:10.1016/j.ophtha.2022.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。